Purpose
The present study aimed to evaluate the long-term results of definitive chemoradiotherapy (CRT) for unresectable locally advanced esophageal squamous cell carcinoma (LA-ESCC).
Materials and methods
We analyzed eighty patients with unresectable LA-ESCC, who underwent definitive CRT between 2001 and 2014. The 5-year overall survival (OS), cause-specific survival (CSS), and progression-free survival (PFS) rates were calculated, and we investigated the prognostic factors and adverse events.
Results
The median age was 66 years (range, 41–83 years). Histologically, all patients had squamous cell carcinoma. The most common tumor site was the middle thoracic esophagus in 43 (54%) patients. According to the eighth edition of the Union for International Cancer Control TNM classification, sixty-six patients (83%) had T4 disease, 59 (74%) had regional lymph node (LN) metastases, and 35 (44%) had distant LN metastases beyond the regional LN (M1 LYM) disease. Forty-five (56%) and 35 (44%) patients belong to clinical stages IVA and IVB, respectively. The median follow-up period for survivors was 86 months. The 5-year OS, CSS, and PFS rates were 20.2%, 25.7%, and 18.4%, respectively. On univariate analysis, only the performance status score was significantly associated with better overall survival (p = 0.026). Grade 3 or higher late adverse events were observed in 12 (15%) patients, and these included cardiopulmonary adverse events in 6 (8%) patients. Treatment-related death occurred in 3 (4%) patients.
Conclusion
We showed the long-term results of definitive CRT for unresectable LA-ESCC. The survivals are still poor and new treatment strategies need to be developed.
Background: This study aimed to propose a machine learning model to predict the local response of resectable locally advanced esophageal squamous cell carcinoma (LA-ESCC) treated by neoadjuvant chemoradiotherapy (NCRT) using pretreatment 18-fluorodeoxyglucose positron emission tomography (FDG PET) images. Methods: The local responses of 98 patients were categorized into two groups (complete response and noncomplete response). We performed a radiomics analysis using five segmentations created on FDG PET images, resulting in 4250 features per patient. To construct a machine learning model, we used the least absolute shrinkage and selection operator (LASSO) regression to extract radiomics features optimal for the prediction. Then, a prediction model was constructed by using a neural network classifier. The training model was evaluated with 5-fold cross-validation. Results: By the LASSO analysis of the training data, 22 radiomics features were extracted. In the testing data, the average accuracy, sensitivity, specificity, and area under the receiver operating characteristic curve score of the five prediction models were 89.6%, 92.7%, 89.5%, and 0.95, respectively. Conclusions: The proposed machine learning model using radiomics showed promising predictive accuracy of the local response of LA-ESCC treated by NCRT.
Introduction:To compare the efficacy and safety of stereotactic body radiation therapy with or
without transcatheter arterial chemoembolization for patients with small hepatocellular
carcinoma who were ineligible for resection or ablation therapies.Methods:A total of 150 patients with 185 hepatocellular carcinoma (≤3 nodules,
Child-Turcotte-Pugh class A or B, and no vascular or extrahepatic metastases) were
treated with stereotactic body radiation therapy. In principle, transcatheter arterial
chemoembolization was combined before stereotactic body radiation therapy (combination
group), but some patients were treated with stereotactic body radiation therapy alone.
The prescribed dose of stereotactic body radiation therapy was 48 Gy in 4 fractions at
the isocenter and 40 Gy in 4 or 5 fractions at the dose covering 95% of the planning
target volume. The overall survival, progression-free survival, local progression free
survival, and complication rates were retrospectively compared between the groups. Local
progression was defined as irradiated tumor growth in dynamic computed tomography
follow-up. Tumor responses were assessed according to the Modified Response Evaluation
Criteria in Solid Tumors. Treatment-related toxicities were evaluated according to the
Common Terminology Criteria for Adverse Events version 4.0.Results:Twenty-eight and 122 patients were enrolled in the stereotactic body radiation therapy
alone and combination groups, respectively. The median follow-up periods were 16 and 29
months, respectively. The 2-year overall, progression-free, and local progression-free
survival times in stereotactic body radiation therapy alone and combination groups were
78.6% and 80.3% (P = .6583), 49.0% and 42.9% (P =
.188), and 71.4% and 80.8% (P = .9661), respectively. The incidence of
≥grade 3 toxicities was 17.9% in stereotactic body radiation therapy alone group and
18.9% in combination group (P = .903).Conclusions:Stereotactic body radiation therapy alone may be a good treatment option for patients
with small hepatocellular carcinoma who were ineligible for resection or ablation
therapies.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.